Boehringer Ingelheim 'surprised' by timing of Roche drug approval

October 16, 2014 9:11 PM

5 0

Boehringer Ingelheim 'surprised' by timing of Roche drug approval

DANBURY -- Executives with Boehringer Ingelheim were elated this week to learn that the FDA approved Ofev, a drug in development for more than 16 years for the treatment of a fatal lung disease that has no cure.

Many were surprised, however, when the U.S. Food and Drug Administration also approved'on the same day ' a drug that Boehinger Ingelheim's competitor, Roche, has also been developing to treat the disease.

Read more

To category page

Loading...